Denmark-based AI immunology company Evaxion Biotech has launched its new AI platform, ObsERV, which has the ability to detect new targets for personalized cancer treatment. This technology could allow medical professionals to treat patients who are currently unresponsive to cancer immunotherapy.
The new platform detects unique virus targets known as ERVs (endogenous retroviruses), which are expressed in cancer cells and are patient-specific. Evaxion's research has shown that high levels of ERVs are strongly correlated with the overall survival of cancer patients, especially patients who do not respond well to immunotherapy.
Based in Denmark, Evaxion Biotech is a biotechnology company specializing in the discovery and development of immunotherapies against cancer and other diseases using its two internally developed AI-based platforms that leverage the power of neural networks and Big Data. Evaxion has employed AI technology to decode the immune system, enabling them to locate ERVs that are unique to each patient.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.